AstraZeneca and POZEN have submitted a Marketing Authorisation Application (MAA) in the EU via the Decentralised Procedure (DCP) for VIMOVO (enteric-coated naproxen/immediate release esomeprazole magnesium, formerly known as
The FDA has approved GlaxoSmithKline’s (GSK) Cervarix [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic
Quidel has reported total revenue of $56.2m, an increase of 76% from $31.9m, for third quarter of fiscal year ended September 30, 2009. During the quarter the company
GlaxoSmithKline (GSK) has reported results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine, which demonstrated that one dose of the vaccine can provide a strong
The FDA has granted marketing approval to Sanofi Aventis, US, for Elitek (rasburicase), for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia,
The International AIDS Vaccine Initiative (IAVI) has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates for
Cancer Therapeutics has signed a letter of intent to acquire another 26% interest in NanoTherapies, bringing the former’s stake to 51% and giving it a controlling interest of
Toray Industries (Toray) has obtained approval in Japan to add a new indication to its natural-type interferon beta preparation Feron, for the improvement of viraemia in chronic hepatitis
Generex Biotechnology (Generex) together with Continental Pharma Laboratories, the company’s importation, marketing, distribution, and sales agent in Algeria, has reported the launch of commercial sales of Generex Oral-lyn
Teva Pharmaceutical Industries (Teva) has commented on the abbreviated new drug application (ANDA) containing a Paragraph IV certification for Copaxone (glatiramer acetate injection), filed by Mylan Pharmaceuticals. Teva
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.